Cargando…

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)

Hemophilia B (HB) is a bleeding disorder caused by deficiency of or defect in blood coagulation factor IX (FIX) inherited in an X-linked manner. It results from one of over 1000 known pathogenic variants in the FIX gene, F9; missense and frameshift changes predominate. Although primarily males are a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Miller, Connie H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627312/ https://www.ncbi.nlm.nih.gov/pubmed/34848993 http://dx.doi.org/10.2147/TACG.S288256

Ejemplares similares

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B
por: Xie, Chen, et al.
Publicado: (2019)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
por: Nayak, Sushrusha, et al.
Publicado: (2011)

Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX
por: Ramaswamy, Suvasini, et al.
Publicado: (2018)

Identification and Genetic Analysis of a Factor IX Gene Intron 3 Mutation in a Hemophilia B Pedigree in China
por: Cao, Dong-Hua, et al.
Publicado: (2014)

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
por: Haurigot, Virginia, et al.
Publicado: (2010)

CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs
por: Chen, Jiahuan, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

The Molecular Basis of FIX Deficiency in Hemophilia B
por: Shen, Guomin, et al.
Publicado: (2022)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
por: Larson, Emily A., et al.
Publicado: (2021)

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B
por: Rogers, Geoffrey L, et al.
Publicado: (2014)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
por: O’Donovan, Mairead, et al.
Publicado: (2021)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
por: von Drygalski, Annette, et al.
Publicado: (2022)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies
por: Al-Allaf, Faisal A., et al.
Publicado: (2017)

The CDC Hemophilia B mutation project mutation list: a new online resource
por: Li, Tengguo, et al.
Publicado: (2013)

Preimplantation genetic diagnosis of hemophilia A
por: Chen, Ming, et al.
Publicado: (2016)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience
por: Bouyadmar, Meryem, et al.
Publicado: (2022)

CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
por: Guan, Yuting, et al.
Publicado: (2016)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Etranacogene dezaparvovec for hemophilia B gene therapy
por: Thornburg, Courtney D.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mejms0qnr733197fgpl5m45e7i